- Home
- FBRX vs TLSA Comparison
FBRX vs TLSA Comparison
Compare FBRX & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- TLSA
- Stock Information
- Founded
- FBRX N/A
- TLSA 2013
- Country
- FBRX United States
- TLSA United Kingdom
- Employees
- FBRX N/A
- TLSA N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- FBRX Health Care
- TLSA Health Care
- Exchange
- FBRX Nasdaq
- TLSA Nasdaq
- Market Cap
- FBRX 76.1M
- TLSA 87.8M
- IPO Year
- FBRX N/A
- TLSA 2000
- Fundamental
- Price
- FBRX $10.98
- TLSA $0.82
- Analyst Decision
- FBRX Strong Buy
- TLSA
- Analyst Count
- FBRX 4
- TLSA 0
- Target Price
- FBRX $77.58
- TLSA N/A
- AVG Volume (30 Days)
- FBRX 27.5K
- TLSA 396.2K
- Earning Date
- FBRX 03-17-2025
- TLSA 03-04-2025
- Dividend Yield
- FBRX N/A
- TLSA N/A
- EPS Growth
- FBRX N/A
- TLSA N/A
- EPS
- FBRX N/A
- TLSA N/A
- Revenue
- FBRX N/A
- TLSA N/A
- Revenue This Year
- FBRX N/A
- TLSA N/A
- Revenue Next Year
- FBRX N/A
- TLSA N/A
- P/E Ratio
- FBRX N/A
- TLSA N/A
- Revenue Growth
- FBRX N/A
- TLSA N/A
- 52 Week Low
- FBRX $4.11
- TLSA $0.41
- 52 Week High
- FBRX $28.68
- TLSA $1.74
- Technical
- Relative Strength Index (RSI)
- FBRX 36.53
- TLSA 54.65
- Support Level
- FBRX $9.81
- TLSA $0.65
- Resistance Level
- FBRX $13.13
- TLSA $0.94
- Average True Range (ATR)
- FBRX 1.52
- TLSA 0.06
- MACD
- FBRX -0.08
- TLSA 0.02
- Stochastic Oscillator
- FBRX 18.17
- TLSA 61.26
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.